ArticleTransfusion2025
Prevalence of HIV, HBV, and HCV in United States blood donations, 2015-2023: The transfusion-transmissible infections monitoring system (TTIMS).
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe Transfusion-Transmissible Infections Monitoring System assesses trends in ~60% of the US blood supply. Donors with high-risk behaviors, including injection drug users, men having sex with other men, or those exchanging sex for money/drugs, were deferred for 12 months (12 M) from 2016 to 2020 and 3 months (3M) from 2020 to 2023. Here we evaluate HIV, HBV, and HCV donation prevalence annually from 2015 to 2023 and in two comparison periods of pre-3M (2015-2020) and 3M (2020-2023) to identify differences between the two periods.
methodsAnnual prevalence was assessed for 8 TTIMS years (2015-2023) and compared between the pre-3M and 3M periods. HIV, HBV, and HCV prevalence/100,000 donations (phtd) was calculated based on serology and nucleic acid testing results. Negative binomial regression assessed prevalence using 1-year intervals. Fisher's exact test evaluated prevalence changes between the two periods (α = 0.05).
resultsAnnual HIV and HBV prevalence remained stable, changing slightly from year 1 to 8 (2.5-2.1 phtd for HIV and 6.3-6.6 phtd for HBV). HCV prevalence declined (19.7-9.6 phtd; p <.01). HIV (2.5-2.0 phtd) and HCV (18.4-9.8 phtd) prevalence decreased from pre-3M to 3M (p <.01), while HBV prevalence remained stable (6.5-6.2 phtd; p = .06).
conclusionsDespite reducing donor deferral periods for many infectious risk behaviors, HIV and HBV prevalence were stable, while HCV prevalence declined over 8 years. Either slight or significant declines occurred from the pre-3M to 3M period for all agents. Thus, changes in policy did not adversely impact the current safety of the blood supply with respect to the major infectious disease agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.